Axitinib

CAS号

319460-85-0

分子式

C22H18N4OS

主要靶点

VEGFR|PDGFR|c-Kit

仅限科研使用

Cat No : CM00084

Print datasheet

Synonyms

Inhibitor|Platelet-derived growth factor receptor|PDGFRβ|PDGFR|Vascular endothelial growth factor receptor|阿昔替尼|阿西替尼|VEGFR3|VEGFR2|VEGFR1|VEGFR|AG 013736|AG013736|AG-013736|cKit|c-kit|Axitinib|inhibit



产品信息

CAS号 319460-85-0
分子式 C22H18N4OS
主要靶点 VEGFR|PDGFR|c-Kit
主要通路 血管生成|蛋白酪氨酸激酶|蛋白酪氨酸激酶|蛋白酪氨酸激酶|血管生成
分子量 386.47
纯度 99.81%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 store at low temperature,keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
别名 Inhibitor|Platelet-derived growth factor receptor|PDGFRβ|PDGFR|Vascular endothelial growth factor receptor|阿昔替尼|阿西替尼|VEGFR3|VEGFR2|VEGFR1|VEGFR|AG 013736|AG013736|AG-013736|cKit|c-kit|Axitinib|inhibit

靶点活性

c-Kit:1.7 nM|PDGFRβ:1.6 nM|VEGFR2/KDR: 0.2 nM|VEGFR1/FLT1:0.1 nM|VEGFR2/Flk1:0.18 nM|VEGFR3: 0.1-0.3 nM

体内活性

方法:为检测体内抗肿瘤活性,将 Axitinib (30 mg/kg,0.5% methyl cellulose) 口服给药给携带 A2780、RMG1 或 HeyA8 MDR 肿瘤的 BALB/c nude 小鼠,每天两次,持续 35-40 天。 结果:在 A2780 和 RMG1 模型中,Axitinib 治疗组的肿瘤重量与对照组相比显著降低了 50%,但在 HeyA8 MDR 模型中差异不显著。[2]

体外活性

方法:胶质瘤细胞 U87、T98 和 U251 用 Axitinib (0.1-100 μM) 处理 72 h,通过 MTT assay 测定细胞活力。 结果:治疗 72 h 后,Axitinib 抑制 U87 和 T98 细胞的生长,IC50 值分别为 12.7 μM 和 8.5 μM。相反,U251 细胞对 Axitinib 介导的细胞毒性作用更具抵抗力。[1] 方法:人上皮卵巢癌细胞 A2780、RMG1、HeyA8 和 HeyA8-MDR 用 Axitinib (1-4 μM) 处理 4 h,通过 Western Blot 检测靶点蛋白表达水平。 结果:不同剂量的 Axitinib 治疗以剂量依赖的方式显著降低了 A2780、RMG1 和 HeyA 8中磷酸化 EGFR2 的表达,但在 HeyA8 MDR 细胞中没有。[2]

溶解度

DMSO:9.7 mg/mL (25 mM)

细胞实验

Endothelial or tumor cells were starved for 18 h in the presence of either 1% FBS (HUVEC) or 0.1% FBS (tumor cells). Axitinib was added and cells were incubated for 45 min at 37°C in the presence of 1 mmol/L Na3VO4. The appropriate growth factor was added to the cells, and after 5 min, cells were rinsed with cold PBS and lysed in the lysis buffer and a protease inhibitor cocktail. The lysates were incubated with immunoprecipitation antibodies for the intended proteins overnight at 4°C. Antibody complexes were conjugated to protein A beads and supernatants were separated by SDS-PAGE. The Super Signal West Dura kit was used to detect the chemiluminescent signal [1].

动物实验

AG-013736, a receptor kinase inhibitor of VEGFRs and, at higher doses, PDGFRs (IC50 = 0.1 nmol/L for VEGFR-1, 0.2 nmol/L for VEGFR-2, 0.1–0.3 nmol/L for VEGFR-3, and 1.6 nmol/L for PDGFRβ; ref. 18), was provided by Pfizer Global Research and given once daily by gavage in a volume of 0.13 mL. Control animals received 0.5% carboxymethylcellulose drug carrier. Irradiations were done on nonanesthetized mice using a 137Cs source operating at 2.4 Gy/min. Mice were confined to plastic jigs with tumor-bearing legs extended through an opening in the side, allowing local irradiations. Fractionated doses were given in five daily 2 Gy fractions per week (omitting weekends). For combination treatments, radiotherapy was delivered first, and AG-013736 was given within ~4 h. Mice were sacrificed, and tumors were excised and then quick frozen (using liquid nitrogen) following 1, 2, or 3 weeks of treatment [3].

参考文献

1.Morelli MB, et al. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner. Oncotarget. 2017 Jan 10;8(2):3380-3395.
2.Paik ES, et al. Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer. Sci Rep. 2020 Mar 17;10(1):4904.
3.Fenton BM, et al. The addition of AG-013736 to rractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 2007 Oct 15;67(20):9921-8.
4.Huang M, Chen M, Qi M, et al. Perivascular cell‐derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs[J]. Journal of Extracellular Vesicles. 2021, 10(7): e12096.
5.Wei N, Liang J, Peng S, et al. Design, synthesis, and biological evaluation of axitinib derivatives[J]. Molecules. 2018 Mar 23;23(4).
6.Wei R, Ma Q, Li T, et al. Carbazole alkaloids with antiangiogenic activities from Clausena sanki[J]. Bioorganic chemistry. 2018 Apr;77:387-392.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2